Orexin Receptor Agonists Herald a New Era for Narcolepsy Type 1 Treatment
核心洞察
Orexin receptor 2 (搜索) (OX2R) agonists like oveporexton directly target the orexin deficiency central to narcolepsy type 1 (搜索) pathophysiology, representing a potential paradigm shift in treatment.
Phase 2 trial data for oveporexton (TAK-861) showed significant improvements in sleep latency, Epworth Sleepiness Scale scores, and cataplexy rates without the hepatotoxicity that halted its predecessor.
The FDA accepted Takeda's New Drug Application for oveporexton and granted Priority Review, signaling a potential first-in-class therapy for narcolepsy type 1 (搜索).
The therapeutic landscape for narcolepsy type 1 (搜索) (NT1) is poised for transformation as orexin receptor 2 (搜索) (OX2R) agonists advance toward regulatory approval. These agents directly address the core pathophysiology of NT1—loss of orexin-producing neurons in the lateral hypothalamus—offering a mechanism-based approach that has eluded clinicians since the discovery of the orexin system in 1998.
Oveporexton (TAK-861), an oral, highly selective OX2R agonist developed by Takeda Pharmaceuticals (搜索), has demonstrated robust efficacy in a phase 2, double-blind, placebo-controlled multicenter trial. In 112 patients with NT1 randomized across five arms, oveporexton improved average sleep latency on the Maintenance of Wakefulness Test by 12.5 to 25.4 minutes across dose groups, compared with a decline of 1.2 minutes in the placebo group (p < 0.001 for all comparisons). Mean Epworth Sleepiness Scale total scores dropped from baseline values of 18.0–19.0 to 4.8–8.9 at week 8, while placebo-treated patients saw only a modest change from 18.6 to 16.0. Weekly cataplexy episodes fell from 15.7–31.1 at baseline to 2.1–10.1 at week 8 with oveporexton, compared with a reduction from 23.1 to 9.0 episodes with placebo.
Crucially, no hepatotoxicity was observed with oveporexton, a safety signal that had led to the early termination of its predecessor, TAK-994 (firazorexton). That earlier oral OX2R agonist had shown similarly striking efficacy—least-squares mean changes in sleep latency of up to 32.6 minutes versus −2.5 minutes for placebo at week 8—but was discontinued due to drug-induced liver injury.
The U.S. Food and Drug Administration accepted Takeda's New Drug Application for oveporexton and granted Priority Review, positioning it as a potential first-in-class therapy for NT1. A phase 3 randomized, double-blind, placebo-controlled trial (NCT06470828) has been completed, though results are not yet published, and a long-term extension study (NCT05816382) is following approximately 500 patients over five years.
The orexin system, discovered independently by two groups in 1998, comprises neuropeptides produced in the dorsolateral hypothalamus that stabilize wakefulness and suppress REM sleep. In NT1, autoimmune-mediated destruction of orexin neurons leads to cerebrospinal fluid orexin deficiency (<110 pg/mL), which is present in approximately 96% of patients. This deficiency results in the hallmark symptoms of excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations. The HLA DQB1*0602 haplotype is present in 95% of NT1 patients, though it also occurs in roughly 25% of the general population.
Current pharmacotherapy for NT1 relies heavily on stimulants and wakefulness-promoting agents. Modafinil, a dopamine reuptake inhibitor, reduces Epworth Sleepiness Scale scores by approximately 2.8 points (95% CI 1.7–3.8) and increases Maintenance of Wakefulness Test scores by 4.1 minutes (95% CI 3.4–4.8), according to a meta-analysis of 861 patients. Solriamfetol, a norepinephrine-dopamine reuptake inhibitor, improved ESS by 3.8 points (95% CI 2.5–5.1) and MWT by 9.49 minutes (95% CI 6.3–12.69) in pooled data from 383 patients. Pitolisant, a histamine H3 receptor inverse agonist, reduced ESS by 3.6 points (95% CI 0.9–6.3) and decreased daily cataplexy rates from 65.4% to 9.3% in a study of 61 patients.
Sodium oxybate, a GABAB and GHB receptor agonist, remains a cornerstone therapy. In the phase 3 REST-ON trial of once-nightly dosing, sodium oxybate increased mean sleep latency by 6.13 minutes versus placebo (95% CI 3.52–8.75), reduced weekly cataplexy attacks by 6.65 episodes (95% CI −9.32 to −3.98), and improved ESS by 6.52 points (95% CI −5.47 to −2.26). However, sodium oxybate carries a high treatment burden due to its twice-nightly dosing requirement and the Risk Evaluation and Mitigation Strategy (REMS) safety program, which imposes significant administrative demands on clinicians.
The limitations of existing therapies are well documented. Stimulants carry risks of tolerance, abuse potential, and cardiovascular effects, with long-term use in young adults associated with a 1.17-fold increased risk of cardiomyopathy at one year, rising to 1.57-fold at eight years. Modafinil and armodafinil are contraindicated in pregnancy due to a 12% absolute risk increase of major congenital malformations with first-trimester exposure.
Orexin agonism builds on a foundation of compelling preclinical evidence. Orexin receptor-deficient murine models demonstrated that OX2R-deficient mice, but not OX1R-deficient mice, developed narcolepsy-cataplexy features. Regardless of the mechanism of orexin deficiency, orexin supplementation—whether through pharmacologic intervention or ectopic production—reversed the narcolepsy-cataplexy phenotype, confirming that downstream pathways remain intact.
The intravenous OX2R agonist danavorexton (TAK-925) provided early proof of concept. In a phase 1 study, patients with NT1 receiving danavorexton achieved placebo-adjusted improvements in average sleep latency of up to 36.66 minutes (95% CI 27.34–45.98). However, the nine-hour infusion duration limits its practical clinical utility.
Despite the enthusiasm, important questions remain. The phase 2 oveporexton trial was conducted over only eight weeks, and long-term data on sustained efficacy and tolerability are pending. A retrospective cohort analysis of sodium oxybate use over a median of 35.5 months found that 55.6% of patients experienced at least one side effect and 26.6% discontinued the drug due to intolerable effects—rates far higher than those reported in the original registration trials. Whether similar patterns will emerge with chronic OX2R agonism is unknown.
Additionally, the pivotal trials for both sodium oxybate and oveporexton enrolled patients who could undergo washout periods from all medications, potentially selecting for individuals with less severe disease. Real-world patients often require polypharmacy, which may lead to higher rates of adverse effects and drug discontinuation.
OX2R agonists are also being explored beyond NT1. TAK-360 is currently recruiting for trials in narcolepsy type 2 (搜索) (NCT06952699) and idiopathic hypersomnia (搜索) (NCT06812078), conditions for which no orexin-directed therapies currently exist. Idiopathic hypersomnia, with an estimated prevalence of 10.5 to 12.1 per 100,000 individuals in the United States, remains particularly underserved, with only sodium oxybate carrying FDA approval.
As the field awaits phase 3 results and potential regulatory action, oveporexton represents the most mechanistically targeted approach yet developed for NT1. Whether it becomes a definitive monotherapy or another tool in a multimodal treatment strategy will depend on the durability of its efficacy and safety profile in long-term follow-up.